Intercept Pharmaceuticals (FRA:I4P) FCF Margin % : 18.79% (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Intercept Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2023 was €15.6 Mil. Intercept Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was €83.2 Mil. Therefore, Intercept Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2023 was 18.79%.

As of today, Intercept Pharmaceuticals's current FCF Yield % is -7.89%.

The historical rank and industry rank for Intercept Pharmaceuticals's FCF Margin % or its related term are showing as below:

FRA:I4P' s FCF Margin % Range Over the Past 10 Years
Min: -6068.91 Med: -172.29 Max: -9.57
Current: -19.65

During the past 13 years, the highest FCF Margin % of Intercept Pharmaceuticals was -9.57%. The lowest was -6068.91%. And the median was -172.29%.

FRA:I4P's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -147.71 vs FRA:I4P: -19.65

Intercept Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Intercept Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals FCF Margin % Chart

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-133.97

-94.34

-75.12

-15.90

-9.57

Intercept Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Margin %	Get a 7-Day Free Trial															-21.81	-5.84	-75.93	-27.83	18.79

Competitive Comparison of Intercept Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Intercept Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intercept Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's FCF Margin % falls into.

Intercept Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Intercept Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-25.816	/	269.71
	=	-9.57 %

Intercept Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	15.635	/	83.195
	=	18.79 %

Intercept Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (FRA:I4P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (FRA:I4P) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

305 Madison Avenue, Morristown, NJ, USA, 07960

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Intercept Pharmaceuticals (FRA:I4P) Headlines

No Headlines